In This Section

Program

Please note that this special conference will take place as an in-person event in Boston and will not live-stream content for virtual participation. The conference content will be recorded and made available as an on-demand program after the conference.

CME credit is available for in-person attendance for the designated sessions. On-demand presentations are not eligible for CME.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

Sunday, September 15

monday, September 16

tuesday, September 17

wednesdayday, September 18

Sunday, September 15

REGISTRATION
3-8 P.M.

WELCOME AND Keynote lectures
5:30-7:15 P.M.
CME-Eligible

  • Keynote Lecture
    Eileen M. O’Reilly, Memorial Sloan Kettering Cancer Center, New York, New York
  • Rising Star Keynote
    Joseph D. Mancias, Dana-Farber Cancer Institute, Boston, Massachusetts

Lightning Presentation Session A
7:15-7:35 P.M.
CME-Eligible

POSTER SESSION A AND OPENING RECEPTION
7:45-9:45 P.M.

Monday, September 16

CONTINENTAL BREAKFAST
7-8 A.M.

Plenary Session 1: Cachexia, Diet, and Metabolism
8:15-10 A.M.
CME-Eligible

  • Mechanisms of pancreatic cancer cachexia
    Teresa A. Zimmers, Oregon Health & Science University Knight Cancer Institute, Portland, Oregon
  • Developing therapies for pancreatic cancer cachexia
    Andrew E. Hendifar, Cedars Sinai Medical Center, Los Angeles, California
  • Tobias Janowitz, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York

Short talks selected from proffered abstracts

break
10-10:30 A.M.

PLENARY SESSION 2: Immunology and Immunotherapy
10:30 a.m.-12:15 p.m.
CME-Eligible

  • The tumor-reactive CD8+ T-cell repertoire in pancreatic cancer as revealed by single-cell sequencing
    Rienk Offringa, German Cancer Research Center, Heidelberg, Germany
  • Investigating the role of CD4 T cells in the pancreatic tumor microenvironment
    Katelyn T. Byrne, Oregon Health and Science University, Portland, Oregon
  • Exploiting functional specialization of myeloid-derived suppressor cells to overcome therapeutic resistance in pancreatic cancer
    Jashodeep Datta, University of Miami Miller School of Medicine, Miami, Florida

Short talks selected from proffered abstracts

Free time/lunch on own
12:15-2:30 p.m.

Plenary Session 3: Stromal Aspects of the Microenvironment and Tumor Microenvironment
2:30-4:15 p.m.
CME-Eligible

  • Mechanisms and consequences of pancreatic cancer stromal evolution
    Mara Sherman, Memorial Sloan Kettering Cancer Center, New York, New York
  • Targeting the tumor microenvironment to improve responses to therapy
    David G. DeNardo, Washington University School of Medicine in St. Louis, St. Louis, Missouri
  • Functional heterogeneity of fibroblast populations in pancreatic cancer
    Giulia Biffi, University of Cambridge, Cancer Research UK Cambridge Institute, Cambridge, United Kingdom

Short talks selected from proffered abstracts

lightning presentation b
4:15-4:35 P.M.

Poster session b/reception
4:45-6:45 P.m.

Tuesday, September 17

CONTINENTAL BREAKFAST
7-8 A.M.

Plenary Session 4: KRAS Resistance, Mechanisms, and Therapeutics
8:15-10 A.M.
CME-Eligible

  • Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer
    Andrew Aguirre, Dana-Farber Cancer Institute, Boston, Massachusetts
  • Adaptation and resistance to pan-RAS inhibition in pancreatic ductal adenocarcinoma
    Kenneth P. Olive, Columbia University Irving Medical Center, New York, New York
  • Targeting the oncogenic state of RAS with tri-complex inhibitors
    Mallika Singh, Revolution Medicines, Redwood City, California

Short talks selected from proffered abstracts

break
10-10:30 A.M.

Plenary Session 5: KRAS Cell Biology
10:30 a.m.-12:30 p.m.
CME-Eligible

  • Targeting KRAS for pancreatic cancer treatment
    Channing Der, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
  • Piro Lito, Memorial Sloan Kettering Cancer Center, New York, New York
  • Elucidation of metabolic resistance mechanisms to RAS inhibition
    Kirsten Bryant, University of North Carolina, Chapel Hill, North Carolina
  • Christopher M. Counter, Duke University School of Medicine, Durham, North Carolina

Short talks selected from proffered abstracts

Free time/lunch on own
12:30-2:45 p.m.

Plenary Session 6: Early Detection and Interception of Precursor Lesions
2:45-4:30 P.M.
CME-Eligible

  • Peter J. Allen, Duke University School of Medicine, Durham, North Carolina
  • Multimodal tools for noninvasive cancer monitoring
    Erica D. Pratt, Boston University, Boston, Massachusetts
  • Improving pancreatic cancer early detection using a tumor marker gene test
    Michael G. Goggins, Johns Hopkins University, Baltimore, Maryland

Short talks selected from proffered abstracts

Break
4:30-4:50 P.M.

Plenary Session 7: tumor cell biology
4:50-6:25 P.M.
CME-Eligible

  • Targeting Syndecan1 in pancreatic cancer
    Wantong Yao, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • Stress-induced O-glycans drive immunosuppression in pancreatic cancer
    Tobiloba Oni, Whitehead Institute, Cambridge, Massachusetts
  • Metabolic adaptations to autophagy inhibition
    Christina Towers, The Salk Institute for Biological Studies, La Jolla, California

Short talks selected from proffered abstracts

lightning presentation session c
6:30-6:50 p.m.

poster session c/reception
7-9 p.m.

Wednesday, September 18

CONTINENTAL BREAKFAST
7-8 A.M.

Plenary Session 8: plasticity
8-10 a.m.
CME-Eligible

  • Stephanie K. Dougan, Dana-Farber Cancer Institute, Boston, Massachusetts
  • Regulation of tumor and stromal cell plasticity by metabolic stress
    Cosimo Commisso, Sanford Burnham Prebys, San Diego, California
  • Christine Chio, Columbia University, New York, New York
  • Nicholas T. Woods, University of Nebraska Medical Center, Omaha, Nebraska

break
10-10:20 A.M.

Plenary Session 9: metabolism
10:20 A.M.-12:20 p.m.
CME-Eligible

  • Alec C. Kimmelman, NYU Langone Health, New York, New York
  • Systemic metabolic networks in pancreatic cancer and associated cachexia
    Nada Kaalany, Harvard Medical School / Boston Children’s Hospital, Boston, Massachusetts
  • Costas A. Lyssiotis, University of Michigan Medical School, Ann Arbor, Michigan
  • Metabolic competition in pancreatic tumor microenvironment regulates innate immune responses
    Kamiya Mehla, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

debate: Have We Learned Anything from the KRAS Inhibitors That We Didn’t Already Know from Mice?
12:30-1:15 p.m.
CME-Eligible

Departure
1:15 p.m.